Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
HIF-2α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron
Rashi Singhal, … , Costas A. Lyssiotis, Yatrik M. Shah
Rashi Singhal, … , Costas A. Lyssiotis, Yatrik M. Shah
Published April 29, 2021
Citation Information: J Clin Invest. 2021;131(12):e143691. https://doi.org/10.1172/JCI143691.
View: Text | PDF
Research Article Metabolism Oncology

HIF-2α activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron

  • Text
  • PDF
Abstract

Hypoxia is a hallmark of solid tumors that promotes cell growth, survival, and metastasis and confers resistance to chemo and radiotherapies. Hypoxic responses are largely mediated by the transcription factors hypoxia-inducible factor 1α (HIF-1α) and HIF-2α. Our work demonstrates that HIF-2α is essential for colorectal cancer (CRC) progression. However, targeting hypoxic cells is difficult, and tumors rapidly acquire resistance to inhibitors of HIF-2α. To overcome this limitation, we performed a small molecule screen to identify HIF-2α–dependent vulnerabilities. Several known ferroptosis activators and dimethyl fumarate (DMF), a cell-permeable mitochondrial metabolite derivative, led to selective synthetic lethality in HIF-2α–expressing tumor enteroids. Our work demonstrated that HIF-2α integrated 2 independent forms of cell death via regulation of cellular iron and oxidation. First, activation of HIF-2α upregulated lipid and iron regulatory genes in CRC cells and colon tumors in mice and led to a ferroptosis-susceptible cell state. Second, via an iron-dependent, lipid peroxidation–independent pathway, HIF-2α activation potentiated ROS via irreversible cysteine oxidation and enhanced cell death. Inhibition or knockdown of HIF-2α decreased ROS and resistance to oxidative cell death in vitro and in vivo. Our results demonstrated a mechanistic vulnerability in cancer cells that were dependent on HIF-2α that can be leveraged for CRC treatment.

Authors

Rashi Singhal, Sreedhar R. Mitta, Nupur K. Das, Samuel A. Kerk, Peter Sajjakulnukit, Sumeet Solanki, Anthony Andren, Roshan Kumar, Kenneth P. Olive, Ruma Banerjee, Costas A. Lyssiotis, Yatrik M. Shah

×

Figure 5

ROS generation and iron accumulation are involved in DMF and FG4592–mediated cell death in CRC cells.

Options: View larger image (or click on image) Download as PowerPoint
ROS generation and iron accumulation are involved in DMF and FG4592–medi...
Cell death assay in HCT116 and SW480 cells treated with DMF (25 and 75 μM) (A) cotreated with DMF and FG4592 (100 μM) (B) cultured under hypoxia with or without NAC (5 mM). Data are represented as mean ± SD from 3 independent experiments. Statistical significance was calculated using unpaired t test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. ROS measurements in HCT116 and SW480 cells (C) treated with FG4592 (100 μM), DMF (50 μM), or DMF and FG4592 with or without NAC. (D) Cells treated with DMF and cultured in normoxia and hypoxia with or without NAC. Data are plotted as the mean ± SEM from 3 independent experiments. Statistical significance was calculated using 1-way ANOVA with Tukey’s multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (E) ROS measurements in shRNA-mediated HIF-1α, HIF-2α knockdown, and non–target scrambled HCT116 and SW480 cells treated with DMF (50 μM) either alone or in combination with FG4592 (100 μM). Statistical significance was calculated using 2-way ANOVA with Tukey’s multiple comparison. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (F) Heatmap showing the relative abundance of mitochondrial metabolites in FG4592-treated (100 μM) and DMF-treated (50 μM) HCT116 and SW480 cells. (G) Cell death and (H) ROS measurements using FG4592 (100 μM) and DMF (75 μM) either alone or under cotreated conditions in the presence of normal iron (control) and low iron. Statistical significance was calculated using unpaired t test. **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts